Liu J - Search Results

1

Efficacy and safety of nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy in HER2-negative breast cancer.

Yang M, Qu H, Liu A, Liu J, Sun P, Li H. Yang M, et al. Among authors: liu j, liu a. J Cancer Res Ther. 2019;15(7):1561-1566. doi: 10.4103/jcrt.JCRT_241_19. J Cancer Res Ther. 2019. PMID: 31939438 Free article.

2

Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer.

Gong W, Sun P, Mu Z, Liu J, Yu C, Liu A. Gong W, et al. Among authors: liu j, liu a. Anticancer Res. 2017 Aug;37(8):4687-4691. doi: 10.21873/anticanres.11873. Anticancer Res. 2017. PMID: 28739772

3

Clinicopathologic characteristics and prognostic factors in patients with operable HER-2 overexpressing breast cancer.

Liu AN, Sun P, Liu JN, Ma JB, Qu HJ, Zhu H, Yu CY, Zhang LM. Liu AN, et al. Asian Pac J Cancer Prev. 2012;13(4):1197-201. doi: 10.7314/apjcp.2012.13.4.1197. Asian Pac J Cancer Prev. 2012. PMID: 22799305 Free article.

4

Expression of glucosylceramide synthase in invasive ductal breast cancer may be correlated with high estrogen receptor status and low HER-2 status.

Liu J, Sun P, Sun Y, Liu A, You D, Jiang F, Sun Y. Liu J, et al. Among authors: liu a. Diagn Pathol. 2014 Jan 23;9:22. doi: 10.1186/1746-1596-9-22. Diagn Pathol. 2014. PMID: 24456584 Free PMC article.

5

Altered methylation of glucosylceramide synthase promoter regulates its expression and associates with acquired multidrug resistance in invasive ductal breast cancer.

Liu J, Zhang X, Liu A, Zhang D, Su Y, Liu Y, You D, Yuan L, Kong X, Wang X, Sun P. Liu J, et al. Among authors: liu y, liu a. Oncotarget. 2016 Jun 14;7(24):36755-36766. doi: 10.18632/oncotarget.9337. Oncotarget. 2016. PMID: 27191984 Free PMC article.

6

Prognostic value of using glucosylceramide synthase and cytochrome P450 family 1 subfamily A1 expression levels for patients with triple-negative breast cancer following neoadjuvant chemotherapy.

Liu J, Wang S, Wang C, Kong X, Sun P. Liu J, et al. Exp Ther Med. 2021 Mar;21(3):247. doi: 10.3892/etm.2021.9678. Epub 2021 Jan 22. Exp Ther Med. 2021. PMID: 33603855 Free PMC article.

7

Analysis of the differences of serum protein mass spectrometry in patients with triple negative breast cancer and non-triple negative breast cancer.

Liu AN, Sun P, Liu JN, Yu CY, Qu HJ, Jiao AH, Zhang LM. Liu AN, et al. Tumour Biol. 2014 Oct;35(10):9751-7. doi: 10.1007/s13277-014-2221-5. Epub 2014 Jun 29. Tumour Biol. 2014. PMID: 24972967

8

Pathological cytomorphologic features and the percentage of ALK FISH-positive cells predict pulmonary adenocarcinoma prognosis: a prospective cohort study.

Jiang F, Wang C, Yang P, Sun P, Liu J. Jiang F, et al. Among authors: liu j. World J Surg Oncol. 2021 Sep 16;19(1):278. doi: 10.1186/s12957-021-02386-0. World J Surg Oncol. 2021. PMID: 34530849 Free PMC article.

9

Partial response to Zercepac® plus chemotherapy in triple-positive advanced breast cancer with changed molecular typing.

Jiang F, Li J, Wang C, Li M, Cao Y, Sun P, Liu J. Jiang F, et al. Among authors: liu j. Minerva Med. 2022 Jul 5. doi: 10.23736/S0026-4806.22.08243-X. Online ahead of print. Minerva Med. 2022. PMID: 35785954 Free article. No abstract available.

10

Prognostic value of insulin-like growth factor 2 mRNA-binding protein 3 and vascular endothelial growth factor-A in patients with primary non-small-cell lung cancer.

Liu J, Liu Y, Gong W, Kong X, Wang C, Wang S, Liu A. Liu J, et al. Among authors: liu y, liu a. Oncol Lett. 2019 Nov;18(5):4744-4752. doi: 10.3892/ol.2019.10835. Epub 2019 Sep 10. Oncol Lett. 2019. PMID: 31611984 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

144,152 results

Search Page

Filters